NCT04781374撤回2 期
A Phase 2 Study of Neratinib in Patients With Metastatic Castration Resistant Prostate Cancer and Increased Human Epithelial Growth Factor Receptor 2 (HER2) Signaling
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 撤回
- 试验地点
- 3
- 主要终点
- Response Rate to Neratinib
研究概览
简要总结
This research study is examining whether Neratinib has any activity in participants with prostate cancer that has spread and is no longer responding to hormonal treatment.
- The names of the study drug involved in this study is neratinib.
详细描述
In this research study, investigators are testing neratinib in prostate cancer that has spread and is no longer responding to hormonal therapies. This research study involves testing tumors for evidence of increased HER2 signaling, and treating those who do have increased HER2 signaling with a targeted therapy.
The research study procedures include: screening for eligibility and study treatment including evaluations and follow up visits.
- The names of the study drug involved in this study is neratinib. It is expected that about 14 people will take part in this research study.
This research study is a Phase II clinical trial. Phase II clinical trials test the safety and effectiveness of an investigational drug to learn whether the drug works in treating a specific disease.
"Investigational" means that the drug is being studied. The U.S. Food and Drug Administration (FDA) has not approved neratinib for this specific disease but it has been approved for other uses.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- Male
- 接受健康志愿者
- 否
入选标准
- •Histologically or cytologically confirmed metastatic prostate adenocarcinoma (secondary components of variant histology are acceptable).
- •Castration-resistance, with progression on medical/surgical castration and confirmed baseline testosterone <50ng/dL
- •Ongoing castration, either with prior orchiectomy or ongoing gonadotropin releasing hormone (GnRH) agonist/antagonist therapy as per investigator discretion
- •Anti-resorptive therapy (e.g. denosumab, bisphosphonates) is allowable at any point
- •Prior progression on (or intolerance of) at least one androgen-receptor signaling inhibitor(i.e. abiraterone, enzalutamide, apalutamide, darolutamide). Progression is per investigator and can include prostate specific antigen (PSA), symptomatic, and/or radiographic progression. There is no limit to prior therapies, nor any requirement on taxane treatments.
- •Positive biomarker (phospho human epidermal growth factor receptor 2, pHER2) assessment on baseline tissue. Archival tissue is acceptable but must have been acquired during or after prior abiraterone and/or enzalutamide therapy and must meet tissue specifications outlined in the biomarker assessment section of the protocol. If suitable archival tissue is not available, then the patient must be willing to undergo a research biopsy to obtain tissue for biomarker assessment.
- •Evaluable for response, defined as at least one of the following:
- •Baseline PSA >=2.0 ng/mL
- •Measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
- •Ability to understand and willingness to sign informed consent.
- •Willingness to undergo research biopsy on study, as well as at baseline if needed to obtain tissue for biomarker assessment.
- •Age >=18 years
- •Eastern Cooperative Oncology Group (ECOG) performance status ≤2
- •Adequate organ and marrow function as defined below:
- •leukocytes ≥2,000/mcL
- •absolute neutrophil count ≥1,500/mcL
- •platelets ≥100,000/mcL
- •total bilirubin ≤ 1.5 x institutional upper limit of normal (ULN), unless participant has known or suspected Gilbert's syndrome
- •AST(SGOT)/ALT(SGPT) ≤2.5 × institutional ULN or <=5 x ULN if liver metastases present
- •Estimated glomerular filtration rate (eGFR) ≥ 30 mL/min
- •Male participants must agree to use contraception with any female partners who are of reproductive potential prior to the study entry, for the duration of the study participation, and 6 months after completion of administration.
- •Human immunodeficiency virus (HIV)-infected participants on effective anti-retroviral therapy with undetectable viral load within 6 months are eligible for this trial.
- •For participants with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated.
- •Participants with a history of hepatitis C virus (HCV) infection must have been treated and cured. For participants with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load.
- •Participants with brain metastases are eligible if (1) brain metastases are asymptomatic and patients are on a stable dose of corticosteroids (if needed) for 14 days prior to enrollment, or (2) brain metastases have been treated with local therapy and follow-up brain imaging shows no evidence of progression.
- •Participants with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial.
- •Participants must be able to swallow pills.
排除标准
- •Use of a strong CYP3A4/CYP2C8 inducer/inhibitor within 3 half-lives prior to first dose of study treatment
- •Participants who are receiving any other investigational agents
- •History of allergic reaction to HER2 inhibitors
- •Child-Pugh class C hepatic impairment
- •Current use of a proton pump inhibitor (no specific wash-out period)
- •Corrected QTc interval >450 msec with institutional standard correction formula. One EKG is sufficient. In the case of potentially reversible causes of QT prolongation (e.g. medications, electrolyte abnormalities), EKG may be repeated once during screening and that result may be used to determine eligibility.
- •Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
- •Uncontrolled baseline diarrhea or uncontrolled predisposition to intermittent diarrhea, e.g. uncontrolled inflammatory bowel diseases.
研究组 & 干预措施
Neratinib
Experimental
The research study procedures include: screening for eligibility and study treatment including evaluations and follow up visits.
- Neratinib-once daily with 28 consecutive days defined as a treatment cycle
干预措施: Neratinib (Drug)
结局指标
主要结局
Response Rate to Neratinib
时间窗: 84 days
defined by PSA response and/or radiographic response after three 28-day cycles of treatment.
次要结局
- Best PSA response(24 Months)
- Progression Free Survival(24 Months)
- Best Radiographic Response(Baseline, Every 3 Cycles through study completion, up to 24 months.)
- Duration of Response(Baseline, Every 3 Cycles through study completion, up to 24 months.)
- Overall Survival(6 Months)
- Number of Participants with Treatment Related Adverse Events as Assessed by CTCAE v5.0(Baseline, through study (up to 24 Months, and until the end of the 30-day post-treatment follow-up.)
研究者
David J. Einstein
Principal Investigator
Beth Israel Deaconess Medical Center
研究点 (3)
Loading locations...
相似试验
已完成
2 期
A Phase 2 Trial of Ponatinib in Participants With Metastatic and/or Unresectable Gastrointestinal Stromal TumorGISTNCT01874665Ariad Pharmaceuticals45
进行中（未招募）
1 期
Phase 2 trial of ponatinib in patients with metastatic and/or unresectable gastrointestinal stromal tumor (GIST) following failure or intolerance of prior therapy with imatinib (POETIG trial – POnatinib after rEsisTance to Imatinib in GIST)EUCTR2015-002285-23-DEniversitaetsklinikum Essen81
终止
2 期
Erdafitinib for the Treatment of Patients With Castration-Resistant Prostate CancerCastration-Resistant Prostate CarcinomaCastration-Resistant Prostate Carcinoma Refractory to Second-Generation Androgen Receptor Axis-Targeted AgentsMetastatic Malignant Neoplasm in the BoneMetastatic Prostate AdenocarcinomaMetastatic Prostate Small Cell Neuroendocrine CarcinomaStage IV Prostate Cancer AJCC v8Stage IVA Prostate Cancer AJCC v8Stage IVB Prostate Cancer AJCC v8NCT04754425M.D. Anderson Cancer Center11
已完成
2 期
Phase II Study of Dasatinib (BMS-354825) for Androgen-deprived Progressive Prostate CancerProstate CancerNCT00385580Bristol-Myers Squibb94
进行中（未招募）
2 期
Neratinib In Combination With Chemotherapy/Trastuzumab/Pembrolizumab In HER2 Gastroesophageal CancerGastroEsophageal CancerGastric CancerNCT06109467H. Lee Moffitt Cancer Center and Research Institute8